Results 221 to 230 of about 55,366 (304)

Orai1 acts as a novel Ca²⁺ signal switch, balancing erythropoiesis through KLF1 regulation. [PDF]

Exp Mol Med
Lee YY, Koh H, Kim J, Kim SU, Lee JH, Park CY.   +5 more
europepmc   +1 more source

Testosterone Versus Clomiphene Treatment of Hypogonadism: A Retrospective Analysis in US Veterans

Andrology, Volume 14, Issue 5, Page 1292-1299, July 2026.
ABSTRACT Background Male hypogonadotropic hypogonadism is a complex condition with a multifactorial etiology. Although testosterone replacement therapy (TRT) is the only approved treatment for male hypogonadism, clomiphene citrate (CC) is often used as an off‐label treatment.
Shourya Tadisina, Elizabeth Cristiano, Thomas Wiegmann, Ken Grasing, Betty Drees, Ram Sharma, Mariana Garcia‐Touza   +6 more
wiley   +1 more source

Ineffective Erythropoiesis Markers in β-Thalassemia: A Systematic Review. [PDF]

J Clin Med
Prahasanti K, Ashariati A, Herawati L, Romadhon PZ, Mahdi BA, Dzakiyah AZ, Cahyono MBA, Yusoff NM.   +7 more
europepmc   +1 more source

Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 2, Page 166-176, July 2026.
Hepcidin levels predict response to iron therapy and support route selection for iron therapy in patients with active inflammatory bowel disease: higher levels favour IV iron, while lower levels indicate likely oral response. Ferritin‐based indices, particularly transferrin/log10(ferritin) and sTfR/log10(ferritin), offer reliable alternatives. ABSTRACT
Lola J. M. Koppelman, Roberta Loveikyte, Rogier L. Goetgebuer, Sander van der Marel, Annemarie C. de Vries, Gerard Dijkstra, Andrea E. van der Meulen‐de Jong, on behalf of the Dutch Iron Study Group, M. Duijvestein, M. van der Have, C. Horjus, W. G. N. Mares, Z. Mujagic, B. Oldenburg, R. West   +14 more
wiley   +1 more source

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 990-1004, July 2026.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source

Daprodustat augments red cell and γ-globin production in models of sickle cell disease. [PDF]

Blood Red Cells Iron
Sharma M, Ishfaq M, Mondal P, Mohideen A, Chowdhury FA, Taiclet S, Philips BJ, Crosby D, Wood KC, Straub AC, Ghosh S, Yien YY, Xu JZ.   +12 more
europepmc   +1 more source

Welfare and Physiological Consequences of Non‐Lethal Blood Sampling From the Caudal Vasculature of Atlantic Salmon (Salmo salar L.)

Journal of Fish Diseases, Volume 49, Issue 7, July 2026.
ABSTRACT The objective of this study was to evaluate welfare and health effects following single and repeated non‐lethal blood sampling from the caudal vasculature of Atlantic salmon. Two experiments were conducted at three different temperatures: a 6‐week freshwater experiment with fish weighing 50–100 g, undergoing up to four blood withdrawals, and a
Harriet Romstad, Camilla Karlsen, Silje Stensby‐Skjærvik, Alf Seljenes Dalum, Maria Banaszkiewicz, Simen Foyn Nørstebø, Jessica Louise Ray, Hege Lund, Torstein Kristensen, Christine Klykken   +9 more
wiley   +1 more source

Molecular profiles of red blood cells across geographic, pathological, and age-related perspectives: translational insights. [PDF]

Front Med (Lausanne)
Almadhaani KY, Altaie AM, Hamoudi R.
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, Volume 13, Issue 31, 4 June 2026.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Stratifying Hepatic Fat in Hemodialysis: The Role of Phenotype and Anemia Therapy. [PDF]

Kidney Med
Ito H, Mori T.
europepmc   +1 more source